In this episode, Tom Caravela welcomes Steve St. Onge to discuss the intricacies of corporate acquisitions within the pharmaceutical industry. Steve shares his journey through corporate development and provides insight into the transition and management of acquisitions, both before and after announcements. The conversation delves into the emotional and strategic aspects of navigating acquisitions, identifying warning signs, and the impact of market volatility. Steve offers practical advice for decision-making during economic downturns and strategies for embracing change and new opportunities in the pharma sector. The episode concludes with a discussion on future innovation and optimism in biotech, along with closing remarks and gratitude to listeners.
Steve St. Onge, Sr Director Business Development and Corporate Communications at Paratek discusses what to expect after your company has been acquired.
Steve shares….
👉 What to expect when acquisition news hits
👉 How to handle emotions and not panic
👉 What steps you should take after acquisition news
👉 What are the warning signs to be aware of
👉 Why is the pharma / biotech sector so volatile these days
Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer
Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal
Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD
E.M. Ray, L.A. Carey, K.E. Reeder-Hayes
Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD
Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai